Inhibitor Therapeutics (INTI) Receivables - Other (2021)

Inhibitor Therapeutics' (INTI) quarterly Receivables - Other came in at -$192500.0 in Q3 2021, down 42.86% on a QoQ basis from -$134750.0 in Q2 2021.

Inhibitor Therapeutics (INTI) Receivables - Other (2021) Analysis & Trends

Inhibitor Therapeutics (INTI) has 1 years of Receivables - Other data on file, last reported at -$192500.0 in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Inhibitor Therapeutics	15.64 Mn	15.64 Mn	-

Download Data